Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine

30 Jul 2019

Abstract excerpt

Construction of an optimal vaccine against tumors relies on the availability of appropriate tumor-specific antigens capable to stimulate CD4+ T helper cells (TH) and CD8+ cytolytic T cells (CTL). CTL are considered the major effectors of the anti-tumor adaptive immune response as they recognize antigens presented on MHC class I (MHC-I) molecules usually expressed in all cells and thus also in tumors. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31417570
DOI: 10.3389/fimmu.2019.01806

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor VaccinePMID 31417570Read ↗

CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approachesSemantic proximity Read ↗

Malignant cell MHC-II immunopeptidomes reveal the evolution of tumor-host interactionsSemantic proximity Read ↗

Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.Semantic proximity Read ↗

CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.Semantic proximity Read ↗

T-Cell-Mediated Killing in Glioblastoma Organoids induced by Adenoviral Delivery of the CIITA TransgeneSemantic proximity Read ↗

Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITASemantic proximity Read ↗

Biological Consequences of MHC-II Expression by Tumor Cells in CancerSemantic proximity Read ↗

Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.Semantic proximity Read ↗

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapySemantic proximity Read ↗

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockadeSemantic proximity Read ↗

MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapySemantic proximity Read ↗

Deciphering the tumor-specific immunopeptidome in vivo with genetically engineered mouse modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.